Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00046254

Enrollment

2127

Registered

2002-09-25

Start date

2002-02-28

Completion date

2007-02-28

Last updated

2012-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Fracture, Osteoporosis

Keywords

hip fracture, recurrent fracture, fracture, bone loss, bisphosphonate, bone mineral density, osteoporosis, zoledronic acid, geriatrics, rehabilitation, elderly, nursing home, orthopedic

Brief summary

The purpose of this study is to evaluate whether zoledronic acid given once yearly for two years to men and women after surgical repair of a recent hip fracture will significantly reduce the rate of all re-occurring (new) osteoporotic fractures. All patients will receive vitamin D and calcium.

Interventions

DRUGZoledronic Acid

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Male or female ages 50 years or older * Must have a recent hip fracture repair in the past 90 days * Must be able to walk with or without assistive device (for example, using a walker) prior to the hip fracture

Exclusion criteria

* Current bisphosphonate users such as aredia (pamidronate), didronel (etidronate), fosamax (alendronate), actonel (residronate), skelid (tiludronate) Other protocol-defined inclusion/

Design outcomes

Primary

Measure	Time frame
Significant reduction in rate of clinical fractures after surgical repair of hip fracture	—

Secondary

Measure	Time frame
Increase in total hip and femoral neck BMDs	—

Countries

Germany, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 6, 2026